Pfizer’s proxy battle with Starboard has gotten messy. It’s the latest in a series of activist investor campaigns that have been on the rise in recent years.
With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble
Pfizer’s proxy battle with Starboard has gotten messy. It’s the latest in a series of activist investor campaigns that have been on the rise in recent years.
